Kronox Lab Sciences to Hold 17th AGM on Sept 16, 2026; Proposes Dividend
Kronox Lab Sciences will hold its 17th AGM on September 16, 2026, via VC/OAVM. The agenda includes adopting FY26 financials and declaring a final dividend of ₹0.50 per share for FY26. The re-appointment of director Jogindersingh Jaswal and ratification of cost auditor remuneration are also on the agenda.
The AGM involves key decisions such as dividend declaration, financial statement adoption, director re-appointment, and auditor remuneration ratification, which are material to shareholders.
The announcement is a routine corporate event (AGM notice) and does not contain information that significantly alters the company's financial outlook or valuation.
Kronox Lab Sciences Limited has announced the notice for its 17th Annual General Meeting (AGM), scheduled to be held on Wednesday, September 16, 2026, at 11:00 AM via Video Conferencing/Other Audio Visual Means (VC/OAVM).
The primary agenda items for the AGM include the adoption of the Audited Standalone Financial Statements for the financial year ended March 31, 2026, along with the Board and Auditors' reports. Additionally, the company proposes to declare a final dividend of ₹0.50 per equity share for the financial year 2025-26.
Other key businesses to be transacted include the re-appointment of Mr. Jogindersingh Jaswal, who retires by rotation, and the ratification of remuneration payable to the Cost Auditors, M/s. Diwanji & Associates, for the financial year 2026-27 at ₹90,000 per annum plus applicable taxes.
The electronic copy of the Notice of AGM and the Annual Report for 2025-26 are being sent to shareholders via email on August 24, 2026. The Register of Members and Share Transfer books will remain closed from September 10, 2026, to September 16, 2026, inclusive, for the purpose of the AGM. The cut-off date for remote e-voting is September 9, 2026.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.